B. Douglas Hoey, RPh, MBA
Hoey is the Chief Executive Officer of the National Community Pharmacists Association. He has spent 20+ years working in and representing community pharmacies.
NCPA represents nearly 23,000 community pharmacies and their pharmacists.
In 2005, Hoey was named COO and helped lead the NCPA team that scored legislative victories requiring prompt pay of Part D claims and winning a court injunction to delay AMP that saved community pharmacies over $2 billion dollars. He is a licensed pharmacist in Oklahoma, Virginia, and Texas and practiced in community and long term care settings contributing to the development of expansions into durable medical equipment and home infusion. Hoey has also developed and taught pharmacology courses at George Washington University and Marymount University.
He is also a member of the Board of Directors for Surescripts and Mirixa.
He is a graduate of the University of Oklahoma College of Pharmacy and the Oklahoma City University business graduate school.
Mark Riley, PharmD, NCPA Past President
NCPA President Mark Riley, is the executive vice president of the Arkansas Pharmacists Association and an authority on pharmacy benefit managers. Riley owns East End Pharmacy in Little Rock, where he was pharmacist-in-charge for 20 years. He earned his bachelor of science in pharmacy and his doctor of pharmacy from the University of Arkansas for Medical Sciences College of Pharmacy. A one-time pharmacy benefit manager (PBM) executive, Riley has been asked by over 160 businesses to advise them on pharmacy benefit management
Lonny Wilson, DPh, NCPA Past President
Past NCPA President Wilson is one of the original founders of Pharmacist Providers of Oklahoma (PPOk), a buying group, switching service, and administrator of managed care drug plans. He has been its CEO since 1989 and owns three pharmacies in the Oklahoma City area. He also is chairman of the board of directors of the medication therapy management company Mirixa, established by NCPA.
One of Wilson's main concerns both at PPOk and NCPA has been the general price erosion in the community pharmacy marketplace and the especially deleterious effect of differing generic drug maximum allowable cost rates on third party contracting.